



MedImmune Influenza Update
2012 National Influenza Vaccine Summit

Seth Feldman
Associate Director, Influenza Franchise



Contents

- Product overview
- Burden of influenza B
- Value of quadrivalent vaccines




MedImmune's Approved Influenza Vaccines

- FluMist
 - ♦ To supply ~13 million doses for the **2012-2013** season
 - ♦ Shipping expected to begin in July – August 2012
 - ♦ More information at www.flumist.com
- FluMist Quadrivalent
 - ♦ Approved by FDA on February 29, 2012
 - ♦ Available for the **2013-2014** season
 - ♦ Prebooking to begin late 2012
 - ♦ More information at www.flumistquadrivalent.com



Influenza B represents a significant burden: ~24% of all circulating influenza, both B lineages co-circulating since 2001

- Influenza B causes seasonal influenza epidemics with resulting morbidity affecting all age groups¹⁻³
- There are two antigenically distinct influenza B lineages – Yamagata and Victoria; there is little or no cross-protection between lineages
- Lineage of circulating B strain did not match vaccine in 5 of 10 US seasons (2001-2011)



1.CDC. *Epidemiology and Prevention of Vaccine-Preventable Diseases*, 2011.
2.Thompson WW, et al. *JAMA*. 2003;289:179-186.
3.Thompson WW, et al. *JAMA*. 2004;292:1333-1340.

Potential value of quadrivalent vaccines

- Quadrivalent vaccines are designed to
 - ◆ Eliminate B-lineage mismatch
 - ◆ Provide broad protection against influenza B
- CDC Outcomes Model
 - ◆ An estimated 2.7 million cases over 8 seasons may have been averted with the use of a quadrivalent vaccine (range: 2,200 to 1,300,000 cases per season)

Limitations of the Model

- > It remains unclear how much *additional* public health benefit would be gained by including a second influenza B strain
- > Vaccine production, vaccine coverage, vaccine efficacy, and virologic circulation are key variables in modeling potential outcomes
- > Season-by-season variability depends on the annual effectiveness of vaccines, the annual population vaccine coverage, the overall burden of influenza during a given season, and the proportion of each influenza B virus lineage circulating

Source: Reed C et al. *Vaccine* 2012.

5

Questions

6